Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Solactis Group is a French biotechnology company specializing in the development and supply of bioscience-based ingredients for the human and animal nutrition markets. As a member of the Greentech Group, the company focuses on gut health through its flagship prebiotic ingredient, galactofructose (lactulose), which is utilized in food, feed, and pharmaceutical applications. Solactis provides clinically-backed solutions designed to improve digestive transit and modulate the intestinal microbiota. Their products are integrated into various consumer goods, including dairy products, dietary supplements, and infant formula. The company operates out of the Biopôle Clermont-Limagne in France, leveraging advanced research in microbiology and nutrition. Solactis is notable for securing the first EFSA-approved health claim for a prebiotic regarding the reduction of intestinal transit time.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Solactis Group.